470 related articles for article (PubMed ID: 18314433)
1. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
[TBL] [Abstract][Full Text] [Related]
2. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
Lynch FL; Dickerson JF; Clarke G; Vitiello B; Porta G; Wagner KD; Emslie G; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes T; DeBar L; McCracken JT; Strober M; Suddath RL; Spirito A; Onorato M; Zelazny J; Iyengar S; Brent D
Arch Gen Psychiatry; 2011 Mar; 68(3):253-62. PubMed ID: 21383263
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
Vitiello B; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes TL; DeBar L; Lynch F; Dickerson J; Strober M; Suddath R; McCracken JT; Spirito A; Onorato M; Zelazny J; Porta G; Iyengar S; Brent DA
J Clin Psychiatry; 2011 Mar; 72(3):388-96. PubMed ID: 21208583
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA
J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849
[TBL] [Abstract][Full Text] [Related]
7. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Brent DA
Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
[No Abstract] [Full Text] [Related]
8. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
9. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy.
Wagner KD; Asarnow JR; Vitiello B; Clarke G; Keller M; Emslie GJ; Ryan N; Porta G; Iyengar S; Ritz L; Zelanzny J; Onorato M; Brent D
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):5-10. PubMed ID: 22251022
[TBL] [Abstract][Full Text] [Related]
10. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.
Woldu H; Porta G; Goldstein T; Sakolsky D; Perel J; Emslie G; Mayes T; Clarke G; Ryan ND; Birmaher B; Wagner KD; Asarnow JR; Keller MB; Brent D
J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):490-8. PubMed ID: 21515198
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Shamseddeen W; Clarke G; Keller MB; Wagner KD; Birmaher B; Emslie GJ; Ryan N; Asarnow JR; Porta G; Brent DA
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):29-36. PubMed ID: 22251024
[TBL] [Abstract][Full Text] [Related]
13. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
[TBL] [Abstract][Full Text] [Related]
16. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
17. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
McMakin DL; Olino TM; Porta G; Dietz LJ; Emslie G; Clarke G; Wagner KD; Asarnow JR; Ryan ND; Birmaher B; Shamseddeen W; Mayes T; Kennard B; Spirito A; Keller M; Lynch FL; Dickerson JF; Brent DA
J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):404-11. PubMed ID: 22449646
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.
Emslie GJ; Mayes T; Porta G; Vitiello B; Clarke G; Wagner KD; Asarnow JR; Spirito A; Birmaher B; Ryan N; Kennard B; DeBar L; McCracken J; Strober M; Onorato M; Zelazny J; Keller M; Iyengar S; Brent D
Am J Psychiatry; 2010 Jul; 167(7):782-91. PubMed ID: 20478877
[TBL] [Abstract][Full Text] [Related]
19. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
20. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
